Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

IGF1-R signals through the RON receptor to mediate pancreatic cancer cell migration.

Jaquish DV, Yu PT, Shields DJ, French RP, Maruyama KP, Niessen S, Hoover H, A Cheresh D, Cravatt B, Lowy AM.

Carcinogenesis. 2011 Aug;32(8):1151-6. doi: 10.1093/carcin/bgr086. Epub 2011 May 11.

2.

The RON-receptor regulates pancreatic cancer cell migration through phosphorylation-dependent breakdown of the hemidesmosome.

Yu PT, Babicky M, Jaquish D, French R, Marayuma K, Mose E, Niessen S, Hoover H, Shields D, Cheresh D, Cravatt BF, Lowy AM.

Int J Cancer. 2012 Oct 15;131(8):1744-54. doi: 10.1002/ijc.27447. Epub 2012 Mar 8.

3.

FAK and IGF-IR interact to provide survival signals in human pancreatic adenocarcinoma cells.

Liu W, Bloom DA, Cance WG, Kurenova EV, Golubovskaya VM, Hochwald SN.

Carcinogenesis. 2008 Jun;29(6):1096-107. doi: 10.1093/carcin/bgn026. Epub 2008 Feb 7.

4.

Tyrosine kinase receptor RON in human pancreatic cancer: expression, function, and validation as a target.

Camp ER, Yang A, Gray MJ, Fan F, Hamilton SR, Evans DB, Hooper AT, Pereira DS, Hicklin DJ, Ellis LM.

Cancer. 2007 Mar 15;109(6):1030-9.

5.

Targeting insulin-like growth factor 1 receptor inhibits pancreatic cancer growth and metastasis.

Subramani R, Lopez-Valdez R, Arumugam A, Nandy S, Boopalan T, Lakshmanaswamy R.

PLoS One. 2014 May 8;9(5):e97016. doi: 10.1371/journal.pone.0097016. eCollection 2014.

6.

Ron knockdown and Ron monoclonal antibody IMC-RON8 sensitize pancreatic cancer to histone deacetylase inhibitors (HDACi).

Zou Y, Howell GM, Humphrey LE, Wang J, Brattain MG.

PLoS One. 2013 Jul 29;8(7):e69992. doi: 10.1371/journal.pone.0069992. Print 2013.

7.

Silencing of RON receptor signaling promotes apoptosis and gemcitabine sensitivity in pancreatic cancers.

Logan-Collins J, Thomas RM, Yu P, Jaquish D, Mose E, French R, Stuart W, McClaine R, Aronow B, Hoffman RM, Waltz SE, Lowy AM.

Cancer Res. 2010 Feb 1;70(3):1130-40. doi: 10.1158/0008-5472.CAN-09-0761. Epub 2010 Jan 26.

8.

The RON receptor tyrosine kinase in pancreatic cancer pathogenesis and its potential implications for future targeted therapies.

Kang CM, Babicky ML, Lowy AM.

Pancreas. 2014 Mar;43(2):183-9. doi: 10.1097/MPA.0000000000000088. Review.

9.

A novel protein isoform of the RON tyrosine kinase receptor transforms human pancreatic duct epithelial cells.

Chakedis J, French R, Babicky M, Jaquish D, Howard H, Mose E, Lam R, Holman P, Miyamoto J, Walterscheid Z, Lowy AM.

Oncogene. 2016 Jun 23;35(25):3249-59. doi: 10.1038/onc.2015.384. Epub 2015 Oct 19.

10.

Synthetic lethality screens reveal RPS6 and MST1R as modifiers of insulin-like growth factor-1 receptor inhibitor activity in childhood sarcomas.

Potratz JC, Saunders DN, Wai DH, Ng TL, McKinney SE, Carboni JM, Gottardis MM, Triche TJ, J├╝rgens H, Pollak MN, Aparicio SA, Sorensen PH.

Cancer Res. 2010 Nov 1;70(21):8770-81. doi: 10.1158/0008-5472.CAN-10-1093. Epub 2010 Oct 19.

11.

Identification of short-form RON as a novel intrinsic resistance mechanism for anti-MET therapy in MET-positive gastric cancer.

Wu Z, Zhang Z, Ge X, Lin Y, Dai C, Chang J, Liu X, Geng R, Wang C, Chen H, Sun M, Guo W, Li J.

Oncotarget. 2015 Dec 1;6(38):40519-34. doi: 10.18632/oncotarget.5816.

12.

The RON receptor tyrosine kinase mediates oncogenic phenotypes in pancreatic cancer cells and is increasingly expressed during pancreatic cancer progression.

Thomas RM, Toney K, Fenoglio-Preiser C, Revelo-Penafiel MP, Hingorani SR, Tuveson DA, Waltz SE, Lowy AM.

Cancer Res. 2007 Jul 1;67(13):6075-82.

14.

Complement component 1, q subcomponent binding protein (C1QBP) in lipid rafts mediates hepatic metastasis of pancreatic cancer by regulating IGF-1/IGF-1R signaling.

Shi H, Fang W, Liu M, Fu D.

Int J Cancer. 2017 Oct 1;141(7):1389-1401. doi: 10.1002/ijc.30831. Epub 2017 Jun 24.

PMID:
28608366
15.

Novel nuclear localization and potential function of insulin-like growth factor-1 receptor/insulin receptor hybrid in corneal epithelial cells.

Wu YC, Zhu M, Robertson DM.

PLoS One. 2012;7(8):e42483. doi: 10.1371/journal.pone.0042483. Epub 2012 Aug 3.

16.

Smad4-dependent TGF-beta signaling suppresses RON receptor tyrosine kinase-dependent motility and invasion of pancreatic cancer cells.

Zhao S, Ammanamanchi S, Brattain M, Cao L, Thangasamy A, Wang J, Freeman JW.

J Biol Chem. 2008 Apr 25;283(17):11293-301. doi: 10.1074/jbc.M800154200. Epub 2008 Feb 29.

17.
18.

Small interfering RNA-directed targeting of RON alters invasive and oncogenic phenotypes of human hepatocellular carcinoma cells.

Cho SB, Park YL, Song YA, Kim KY, Lee GH, Cho DH, Myung DS, Park KJ, Lee WS, Chung IJ, Choi SK, Kim KK, Joo YE.

Oncol Rep. 2011 Dec;26(6):1581-6. doi: 10.3892/or.2011.1435. Epub 2011 Aug 24.

PMID:
21874262
20.

Differential expression of receptor tyrosine kinases (RTKs) and IGF-I pathway activation in human uterine leiomyomas.

Yu L, Saile K, Swartz CD, He H, Zheng X, Kissling GE, Di X, Lucas S, Robboy SJ, Dixon D.

Mol Med. 2008 May-Jun;14(5-6):264-75. doi: 10.2119/2007-00101.Yu. Erratum in: Mol Med. 2008 Jul-Aug;14(7-8):538.

Supplemental Content

Support Center